Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

People using Ozempic say they are losing their desire to drink. It’s anecdotal evidence right now, but this would be a game-changer for those who are trying to break free from addiction.

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Senators Bernie Sanders and Angus King are preparing to introduce legislation that would ban pharmaceutical companies from advertising prescription drugs directly to consumers, The Wall Street Journal ...

Angus King (I-Maine) today introduced the End Prescription Drug Ads Now Act, legislation that would ban prescription drug advertising on television, radio, print, digital platforms and social media.

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug amycretin in 2026. The trials will include ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

The Shapiro administration's plan would limit Ozempic access under Medicaid to save costs. Not everyone is on board.

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...

Denmark-based multinational pharmaceutical company Novo Nordisk will be making available in the Philippines within this year ...